Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico Análisis de costo-efectividad del uso de palivizumab en la profilaxis de pacientes prematuros en México
OBJECTIVE: The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. MATERIAL AND METHODS: A decision tree was developed in preterm groups [<...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Instituto Nacional de Salud Pública,
2012-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|